Evaluation of "SPIDER FX" and "PROTEGE RX" for Carotid Artery Stenting (ESPER-CAS)

Evaluation of "SPIDER FX" and "PROTEGE RX" for Carotid Artery Stenting (ESPER-CAS) - ESPER-CAS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014454

Enrollment

100

Registered

2014-07-02

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carotid artery stenosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To be included in this study, patients must be planned to undergo carotid artery stenting under coverage of general health insurance.

Exclusion criteria

Exclusion criteria: Patients will be excluded if they have any contraindication as per the package insert for the PROTETE RX Carotid Stent System or the SPIDER FX Embolic Protection Device. The products must be used only under coverage of health insurance.

Design outcomes

Primary

Measure	Time frame
All stroke, myocardial infarction, and death within 30 days of the stenting procedure	—

Secondary

Measure	Time frame
Adverse events Ipsilateral ischemic stroke Technical success and patency Number of new ipsilateral ischemic lesions on MRI after the procedure (First imaging obtained 6 hours to 7 days after the stenting procedure)	—

Countries

Japan

Contacts

Public ContactTsuyoshi Ohta

Kokura Memorial Hospital Department of Neurosurgery

espercas100@gmail.com093-511-2000

Outcome results